^
    Back
    Association details:
    Biomarker:HER-2 negative
    Cancer:HER2 Negative Breast Cancer
    Drug:letrozole (Aromatase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Invasive Breast Cancer: HER2-Negative and postmenopausal or premenopausal receiving ovarian ablation or suppression:...Preferred Regimens…First-Line Therapy...Non-steroidal aromatase inhibitor (anastrozole, letrozole)...
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer

    Excerpt:
    ...- Postmenopausal women with diagnosis of breast cancer, metastatic disease or locally advanced disease / Estrogen Receptor positive and HER-2 negative / candidate to receive Letrozole...
    Trial ID:
    NCT01430585
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer

    Excerpt:
    ......
    Trial ID:
    VERITAC-3
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

    Excerpt:
    ...Patients with locally advanced or metastatic breast cancer who are unable to receive radical surgeries/other local therapies, with hormone receptor positive and human epidermal growth factor receptor 2 negative confirmed by tumor histopathology and molecular pathology....
    Trial ID:
    NCT05744687
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

    Excerpt:
    ...- HER2-negative breast cancer based on the most recent tumor biopsy and documented by a local laboratory or medical record....
    Trial ID:
    NCI-2021-12428
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

    Excerpt:
    ...- The tumor must be HER2 negative (negative IHC or FISH)...
    Trial ID:
    NCT03962647
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer

    Excerpt:
    ...Tissue samples from patients with early-stage hormone receptor-positive HER2-negative breast cancer will be collected to compare differences....
    Trial ID:
    NCT05447910
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

    Excerpt:
    ......
    Trial ID:
    NCT05809024
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC

    Excerpt:
    ...with estrogen receptor positive (>10%) on IHC staining and HER2 negative (IHC 0+/1+, or IHC 2+ plus FISH negative)...
    Trial ID:
    ORACLE-RIPA
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

    Excerpt:
    ......
    Trial ID:
    NCT05512416
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.

    Excerpt:
    ...Patient has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+....
    Trial ID:
    LeeBLet
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

    Excerpt:
    ...- Postmenopausal women with hormone receptor-positive and HER-2 negative breast cancer...
    Trial ID:
    NCT01225172
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

    Excerpt:
    ...- HER2 negative breast cancer....
    Trial ID:
    NCT02115048
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery

    Excerpt:
    ...- HER2-negative tumor by Herceptest (0 or +1) OR HER2...
    Trial ID:
    NCT00651976
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

    Excerpt:
    ...Patient has HER2 negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0 or 1+ as per local laboratory testing...
    Trial ID:
    NCT01923168
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer

    Excerpt:
    ...- HER2-negative by ASCO/CAP guideline...
    Trial ID:
    NeoChAI
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Neoadjuvant Endocrine Therapy in Breast Cancer

    Excerpt:
    ...ER-positive (≥50%), PgR-positive (≥50% ), HER2-negative, and previously untreated, non-metastatic primary invasive BC....
    Trial ID:
    NCT03397537
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

    Excerpt:
    ...- HER2 negative...
    Trial ID:
    NCT01105312
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A single-arm, multicenter, exploratory clinical study of CDK4/6 inhibitor combined with letrozole in preoperative treatment of stage II-III HR+, HER2- breast cancer (Luminal type)

    Excerpt:
    ...Postmenopausal or premenopausal/perimenopausal women aged >= 18 years and 10%), progesterone receptor (PR) positive (>1%), HER2 negative. ...
    Trial ID:
    ChiCTR2200057104
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    An unblinded clinical trial for the treatment of a particular subtype of postmenopausal breast cancer where the patient will receive at random either Afatinib plus Letrozole or Letrozole alone Ensayo clínico para el tratamiento de pacientes postmenopáusicas con un subtipo particular de cáncer de mama en el que las pacientes podrán recibir (mediante asignación al azar) Afatinib más Letrozol o Letrozol solo.

    Excerpt:
    ...4.HER2 negative breast cancer. ...
    Trial ID:
    2013-002192-18